Subsequently, we only analyzed the data from TCGA database, and the time-dependent ROC analysis showed that EPOR had better predictive ability for 1-, 3-, and 5-year survival rate in MESO patients (AUC = 0.713, 0.803, 0.918) and for 5-year survival in PAAD patients (AUC = 0.81) (Figure 4B). This evidence concerns the gene EPOR and pancreatic adenocarcinoma.